Named on one round in the feed.
Since 2022-06-13
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Sling Therapeutics A biopharmaceutical company advancing oral linsitinib for thyroid eye disease | Series A Published on thinner evidence, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2022-06-13 | [ LEAD ] |
No one else named on these rounds.